Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Research into new cancer drugs remain strong.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

Drug Target Review

AUGUST 28, 2024

What are the main challenges currently faced in the treatment of chronic liver diseases, and how does Resolution Therapeutics aim to address these challenges? Once a patient develops advanced cirrhosis/end-stage liver disease there are no specific therapies to significantly avoid major decompensations and death in the next few years.

Therapies 114

Therapies Disease Engineering Medical Schools 114

Drug Discovery World

FEBRUARY 10, 2023

Breast cancer retained its position as the most-studied disease area in clinical trials in 2022, despite a drop in activity, according to analysis from analytics company Phesi. The post Breast cancer still top disease area for clinical studies appeared first on Drug Discovery World (DDW). Download the full report.

Disease 130

Disease Clinical Trials Clinical Development Trials 130

Drug Discovery World

APRIL 25, 2023

University of California researchers have dosed the second participant in their clinical trial to identify a potential cure for HIV utilising CAR-T cell therapy. The trial is the first-in-human clinical study investigating the duo CAR-T cell therapy for the treatment of HIV. “We

Research 130

Research Clinical Trials Therapies Clinical Development 130

Drug Discovery World

AUGUST 12, 2022

Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva. . The trial will enrol up to 6,000 participants aged five years and older and will be conducted across 50 sites where Lyme disease is highly endemic. Official comments .

Vaccine 130

Vaccine Disease Trials Pharmaceutical Companies 130

Drug Discovery World

AUGUST 28, 2023

DDW’s Diana Spencer speaks to Peter Hamley , Chief Scientific Officer of Samsara Therapeutics, to understand the role autophagy plays in neurodegenerative diseases and how boosting this process could increase healthspan. DS: Samsara’s autophagy inducing candidate SAM001 will be the first agent of its class to enter clinical trials.

Disease 130

Disease Science Clinical Trials Therapies 130

LifeSciVC

JULY 17, 2024

By Mike Cloonan, Chief Executive Officer of Sionna Therapeutics, as part of the From The Trenches feature of LifeSciVC The drug development process in rare diseases is rife with challenges especially when companies target significant differentiation or first-in-class targets.

Clinical Research 45

Clinical Research Disease Research Clinical Trials 45

Drug Discovery World

OCTOBER 4, 2022

William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . Overcoming sector challenges .

Disease 130

Disease Small Molecule Compound Screening Clinical Development 130

Drug Discovery World

DECEMBER 22, 2022

Shelley McLendon , SVP of Vaccine and Infectious Diseases Program Management at ICON, attended the World Vaccine Congress Europe from 16-19 October 2022 in Barcelona, Spain. Disease surveillance and reporting . Disease surveillance is the collection and monitoring of data on disease within a population.

Vaccine 130

Vaccine Disease Clinical Trials Trials 130

Drug Discovery World

OCTOBER 19, 2022

Following the news that the number of clinical trial recruiting sites in Ukraine has dropped by half since the Russian invasion, DDW’s Diana Spencer examines clinical trial data from analytics company Phesi and speaks to Dr Olena Karpenko , Clinical Research Director at Medical Center Ok!Clinic+ Clinic+.

Clinical Research 130

Clinical Research Research Clinical Trials Trials 130

Drug Target Review

OCTOBER 11, 2023

Almost every one of us will know someone with a neurodegenerative disease such as Alzheimer’s or Parkinson’s. It is less common to know someone with a rare genetic disease; but while individually rare, collectively they have an enormous impact. This will, in turn, slow the progression of, or even halt, the disease.

Disease 113

Disease Treatment Small Molecule Therapies 113

Conversations in Drug Development Trends

JANUARY 24, 2024

Written By: Derek Ansel, MS, CCRA, Executive Director, Therapeutic Strategy Lead, Rare Disease Given that 80% of rare diseases have a genetic etiology, genetic implications should be addressed at the onset of a clinical program to support trial enrollment.

Trials 75

Trials Disease Clinical Trials Clinical Research 75

Conversations in Drug Development Trends

MAY 14, 2024

By: Amy Raymond, Derek Ansel, Nathan Chadwick, & Juliane Mills When choosing a CRO for a rare disease study, what truly sets them apart is their methodology: the CRO’s mindset, their approach to each unique study, and their agility in navigating the inherent complexities of rare disease research.

Disease 81

Disease Clinical Trials Trials Pharmaceutical Companies 81

Broad Institute

NOVEMBER 2, 2023

Bayer and Broad Institute extend cancer therapy research collaboration By Corie Lok November 2, 2023 Breadcrumb Home Bayer and Broad Institute extend cancer therapy research collaboration Long-standing industry-academia collaboration has already resulted in three clinical oncology candidates.

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

The Pharma Data

SEPTEMBER 29, 2021

to enhance outcomes, new treatments which will target kidney-specific disease mechanisms are highly desired,” said Hiddo L. Christian Rommel, Member of the chief Committee of Bayer AG’s Pharmaceutical Division and Head of Research and Development. 1 in 3 adults is at risk for the disease. In the U.S.,

Clinical Development 52

Clinical Development Disease Clinical Trials Trials 52

Drug Target Review

MAY 7, 2024

Why are biomarkers particularly critical in the context of rare diseases? Developing novel therapeutic approaches for rare diseases poses inherent challenges due to the limited populations available for testing. How do AI-enhanced approaches accelerate the drug development process for rare diseases?

Disease 59

Disease Clinical Trials Clinical Pharmacology Trials 59

Cytel

APRIL 10, 2024

Orphan drug designation is a regulatory status granted to pharmaceuticals developed for the treatment of rare diseases. It provides incentives to encourage the research, development, and approval of therapies targeting small patient populations.

Disease 59

Disease Drugs Pharmaceuticals Therapies 59

The Pharma Data

MARCH 23, 2022

Baynes, head of Global Clinical Development (GCD) and Chief Medical Officer, Merck Research Laboratories (MRL), will be retiring from Merck in July. Li, president, Merck Research Laboratories, until his retirement. Li, president, Merck Research Laboratories, until his retirement.

Clinical Development 52

Clinical Development Vaccine Research Laboratories Laboratories 52

Drug Discovery World

JULY 21, 2023

The most impactful drug discovery news this week is all linked with scientific research data. Analysts Phesi revealed that a third of clinical development programmes are cancelled during Phase II, and there were significant trial results for drugs for head and neck cancer and Alzheimer’s disease.

Clinical Trials 130

Clinical Trials Trials Clinical Development Drugs 130

Conversations in Drug Development Trends

APRIL 5, 2024

For others, this rare day is aptly the day we honor rare disease communities. Observed annually on the last day of February since 2008, Rare Disease Day has grown into a global movement for raising awareness, promoting research, and advocating for improved access to rare disease treatments and support services.

Disease 52

Disease Clinical Trials Trials Treatment 52

Conversations in Drug Development Trends

MAY 14, 2024

By: Amy Raymond, Derek Ansel, Nathan Chadwick, & Juliane Mills When choosing a CRO for a rare disease study, what truly sets them apart is their methodology: the CRO’s mindset, their approach to each unique study, and their agility in navigating the inherent complexities of rare disease research.

Disease 52

Disease Clinical Trials Trials Pharmaceutical Companies 52

Cytel

MAY 14, 2024

Written by Angela Vinken and Patti Arsenault Key Opinion Leaders (KOLs) — i.e., trusted, well-respected experts — are crucial in clinical research, especially in rare diseases. The challenge, however, is how to use KOLs wisely — they are often clinicians first and researchers second, and their time is in high demand.

Clinical Trials 59

Clinical Trials Disease Trials Clinical Research 59

Drug Discovery World

JULY 5, 2024

People with FTD who have disease-causing GRN mutations produce a reduced amount of progranulin protein. AVB-101 is a potential one-time therapy designed to stop disease progression by delivering a functional copy of the GRN gene to restore appropriate progranulin levels to affected areas of the brain.

Therapies 147

Therapies Trials Clinical Trials Clinical Development 147

Drug Discovery World

JULY 24, 2023

The most impactful drug discovery news this week is all linked with scientific research data. Analysts Phesi revealed that a third of clinical development programmes are cancelled during Phase II, and there were significant trial results for drugs for head and neck cancer and Alzheimer’s disease.

Clinical Development 130

Clinical Development Trials Research Disease 130

Drug Discovery World

APRIL 24, 2024

Evotec and Variant Bio have announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis. Despite the chronic nature of fibrotic conditions, widespread impact on various organs, and substantial disease burden, there is currently no curative treatment for these conditions.

Treatment 130

Treatment Small Molecule Clinical Development Disease 130

Drug Discovery World

JUNE 6, 2024

Professor Charles Swanton, Cancer Research UK’s chief clinician, said the melanoma trial results were “extremely impressive”, adding: “The new vaccine approach is another piece of the puzzle that will allow more patients to be cured, hopefully, or fewer patients to suffer disease relapse.

Vaccine 147

Vaccine Clinical Trials FDA Approval Research Laboratories 147

Drug Discovery World

JULY 24, 2023

The most impactful drug discovery news this week is all linked with scientific research data. Analysts Phesi revealed that a third of clinical development programmes are cancelled during Phase II, and there were significant trial results for drugs for head and neck cancer and Alzheimer’s disease.

Clinical Development 130

Clinical Development Trials Disease Research 130

Drug Discovery World

AUGUST 22, 2024

Prolonging health span with drug development Life Biosciences aims to restore and prolong a patient’s health span by targeting the underlying biology of ageing and increasing the quality of years one spends in good health compared with just increasing the total number of years one lives.

Therapies 147

Therapies DNA Disease RNA 147

Drug Discovery World

FEBRUARY 26, 2024

It targets an important but previously undrugged membrane GPCR receptor, GPR68, with an extensive body of data  demonstrating promising efficacy in multiple models of fibrotic disease.

Clinical Trials 130

Clinical Trials Drugs Therapies Treatment 130

Drug Discovery World

FEBRUARY 10, 2023

The research will support the clinical development of CTx001, CTx’s lead gene therapy asset for the treatment of GA, by enabling the identification of patients with complement-driven AMD for future interventional studies.

Clinical Development 130

Clinical Development Therapies Disease Treatment 130

Drug Discovery World

NOVEMBER 30, 2023

Transcriptomic analysis indicated that the systemic fibrotic disease gene signature is modulated after 12 weeks, with an increased fibrosis signature score in the placebo group but significantly, a decrease in the same fibrosis signature score following FT011 400mg treatment.

Drug Trials 147

Drug Trials Trials Clinical Trials Drugs 147

Drug Discovery World

OCTOBER 14, 2022

“This long-term collaboration combining Merck’s expertise in immuno-oncology with Moderna’s pioneering mRNA technology has yielded a novel tailored vaccine approach,” said Dr Eliav Barr, Senior Vice President and Head of Global Clinical Development, Chief Medical Officer, Merck Research Laboratories. . “We

Vaccine 244

Vaccine Research Laboratories Laboratories Clinical Development 244

Drug Discovery World

MAY 29, 2024

All 11 trial participants had experienced disease progression in prior immunotherapy treatment before joining the trial. These preliminary findings represent some of the initial positive evidence emerging from the burgeoning field of clinical research on cancer therapies leveraging gut microbiota.

Trials 130

Trials Clinical Trials Treatment Clinical Development 130

The Pharma Data

DECEMBER 10, 2020

Spending several years with Sanofi in Paris, France as a Global safety officer, he then relocated to New Jersey, USA to work in Early and Late Stage Clinical Development in Immunology, when he became the Global Project Head of Dupixent, a medicine that has revolutionized the field of allergic and atopic diseases.

Disease 52

Disease Research Doctors Clinical Development 52

Drug Discovery World

MARCH 5, 2024

In her day-to-day role, she is responsible for the development of UCB’s epilepsy discovery strategy, working with researchers to advance understanding of epilepsies while ensuring candidates for a future clinical treatment pipeline to improve the lives of those living with the condition.

Disease 147

Disease Treatment Research Pharmaceutical Companies 147

Drug Discovery World

FEBRUARY 10, 2023

The top stories: Study shines a light on representation in clinical research A diversity study has shown that clinical trials should use real world diseases epidemiology data, rather than US Census Bureau race and ethnicity data, to ensure enrolment reflects the populations affected by different diseases.

Clinical Trials 130

Clinical Trials Trials Drugs Vaccine 130

The Pharma Data

NOVEMBER 30, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. Novavax completed enrollment of 15,000 participants in a pivotal Phase 3 clinical trial being conducted in the U.K. GAITHERSBURG, Md.,

Clinical Development 52

Clinical Development Vaccine Clinical Trials Immune Response 52